SCHEMBL26075374

SCHEMBL26075374

Cc1ccc2nc(-c3ccc(-c4ccc(OCCC(C)C)cc4)c(F)c3)cc(C=O)c2c1

nearest known ligand 0.36

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ TP53 P04637 1/20 0.36
▸ MAPT P10636 7/20 0.36
▸ DHODH Q02127 4/20 0.35
▸ ALDH1A1 P00352 4/20 0.35
▸ HPGD P15428 3/20 0.35
▸ THRB P10828 2/20 0.35
▸ MAPK1 P28482 1/20 0.34
▸ LMNA P02545 3/20 0.34
▸ NPSR1 Q6W5P4 3/20 0.34
▸ HSP90AA1 P07900 2/20 0.34
▸ MCHR1 Q99705 1/20 0.34
▸ KDM4E B2RXH2 2/20 0.34
▸ PLA2G2A P14555 2/20 0.34
▸ MEN1 O00255 1/20 0.34
▸ RECQL P46063 1/20 0.34
▸ KMT2A Q03164 1/20 0.34
▸ PDE10A Q9Y233 1/20 0.34
▸ KCNH2 Q12809 1/20 0.34
▸ HRH3 Q9Y5N1 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26075378 0.91 XDH (0.39) MAPTDHODHALDH1A1HPGDTHRB
SCHEMBL26075357 0.88 PLA2G2A (0.42) MAPTDHODHALDH1A1HPGDTHRB
SCHEMBL26075362 0.87 PLA2G2A (0.41) MAPTDHODHALDH1A1HPGDTHRB
SCHEMBL26075354 0.87 PLA2G2A (0.41) MAPTDHODHALDH1A1HPGDTHRB
SCHEMBL26075365 0.87 PLA2G2A (0.41) MAPTDHODHALDH1A1HPGDTHRB
SCHEMBL26075360 0.87 PLA2G2A (0.41) MAPTDHODHALDH1A1HPGDTHRB
SCHEMBL26075911 0.86 DHODH (0.50) TP53MAPTDHODHALDH1A1HPGD
SCHEMBL26075369 0.85 KDM4E (0.40) MAPTDHODHALDH1A1HPGDTHRB
SCHEMBL26075337 0.84 MAPT (0.49) TP53MAPTDHODHALDH1A1HPGD
SCHEMBL26075287 0.83 DHODH (0.38) TP53MAPTDHODHMCHR1PLA2G2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230303710-A1 METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE IN COMBINATION WITH AN ANTI-CD38 THERAPEUTIC AGENT OHIO STATE INNOVATION FOUNDATION (US) 2023-09-28 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230303710-A1 METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE IN COMBINATION WITH AN ANTI-CD38 THERAPEUTIC AGENT DHODH, CD38, DPYD TP53 522/4885MAPT 2689/4885DHODH 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback